NUKK Relative Valuation
NUKK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NUKK is overvalued; if below, it's undervalued.
Historical Valuation
Nukkleus Inc (NUKK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Nukkleus Inc (NUKK) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：3.40
Fair
0.00
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Nukkleus Inc. (NUKK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
0.00
EV/EBIT
Nukkleus Inc. (NUKK) has a current EV/EBIT of 0.00. The 5-year average EV/EBIT is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBIT of 0.00 falls within the Strongly Undervalued range.
0.00
PS
Nukkleus Inc. (NUKK) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.
0.00
P/OCF
Nukkleus Inc. (NUKK) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/OCF of 0.00 falls within the Strongly Undervalued range.
0.00
P/FCF
Nukkleus Inc. (NUKK) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Nukkleus Inc (NUKK) has a current Price-to-Book (P/B) ratio of -1.54. Compared to its 3-year average P/B ratio of 61.90 , the current P/B ratio is approximately -102.49% higher. Relative to its 5-year average P/B ratio of -32.14, the current P/B ratio is about -95.21% higher. Nukkleus Inc (NUKK) has a Forward Free Cash Flow (FCF) yield of approximately -4.79%. Compared to its 3-year average FCF yield of -17.77%, the current FCF yield is approximately -73.03% lower. Relative to its 5-year average FCF yield of -11.70% , the current FCF yield is about -59.06% lower.
-1.54
P/B
Median3y
61.90
Median5y
-32.14
-4.79
FCF Yield
Median3y
-17.77
Median5y
-11.70
Competitors Valuation Multiple
The average P/S ratio for NUKK's competitors is 1.08, providing a benchmark for relative valuation. Nukkleus Inc Corp (NUKK) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of NUKK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of NUKK in the past 1 year is driven by Unknown.
People Also Watch
SDST
Stardust Power Inc
3.67USD
-1.61%
ABOS
Acumen Pharmaceuticals Inc
1.83USD
-8.04%
MGX
Metagenomi Inc
1.785USD
-0.83%
SUNS
Sunrise Realty Trust Inc
9.4USD
-0.95%
FRD
Friedman Industries Inc
19.59USD
0.93%
RECT
Rectitude Holdings Ltd
1.69USD
-1.74%
MDXH
MDxHealth SA
3.33USD
-0.30%
HNNA
Hennessy Advisors Inc
9.73USD
-0.51%
CRDL
Cardiol Therapeutics Inc
1.01USD
0.00%
Frequently Asked Questions
Is Nukkleus Inc (NUKK) currently overvalued or undervalued?
Nukkleus Inc (NUKK) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Nukkleus Inc (NUKK) is between to according to relative valuation methord.
What is Nukkleus Inc (NUKK) fair value?
NUKK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Nukkleus Inc (NUKK) is between to according to relative valuation methord.
How does NUKK's valuation metrics compare to the industry average?
The average P/S ratio for NUKK's competitors is 1.08, providing a benchmark for relative valuation. Nukkleus Inc Corp (NUKK) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Nukkleus Inc (NUKK) as of Jan 08 2026?
As of Jan 08 2026, Nukkleus Inc (NUKK) has a P/B ratio of -1.54. This indicates that the market values NUKK at -1.54 times its book value.
What is the current FCF Yield for Nukkleus Inc (NUKK) as of Jan 08 2026?
As of Jan 08 2026, Nukkleus Inc (NUKK) has a FCF Yield of -4.79%. This means that for every dollar of Nukkleus Inc’s market capitalization, the company generates -4.79 cents in free cash flow.
What is the current Forward P/E ratio for Nukkleus Inc (NUKK) as of Jan 08 2026?
As of Jan 08 2026, Nukkleus Inc (NUKK) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Nukkleus Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Nukkleus Inc (NUKK) as of Jan 08 2026?
As of Jan 08 2026, Nukkleus Inc (NUKK) has a Forward P/S ratio of 0.00. This means the market is valuing NUKK at $0.00 for every dollar of expected revenue over the next 12 months.